KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eli Lilly (LLY) Interest & Investment Income (2009 - 2012)

Eli Lilly posted quarterly Interest & Investment Income of $26.1 million for Q1 2012, up 68.39% year-on-year from $15.5 million in Q2 2011, and up 6.97% on a QoQ basis from $24.4 million in Q4 2011.

Eli Lilly (LLY) has 4 years of Interest & Investment Income data on file, last reported at $26.1 million in Q1 2012.

  • For the quarter ending Q1 2012, Interest & Investment Income rose 68.39% year-over-year to $26.1 million; the trailing twelve-month figure through Mar 2012 stood at $90.5 million (up 59.33% YoY), and the FY2011 full-year result was $79.9 million, up 53.95% from the prior year.
  • Interest & Investment Income for Q1 2012 stood at $26.1 million, up from $24.4 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $718.7 million in Q3 2009 and bottomed at $10.6 million in Q1 2010.
  • The 4-year median for Interest & Investment Income is $17.8 million (2011), against an average of $81.4 million.
  • The widest annual swing landed in 2010, when Interest & Investment Income tumbled 97.73%; it then soared 74.29% in 2011.
  • A 4-year view of Interest & Investment Income shows it stood at $718.7 million in 2009, then plunged by 98.05% to $14.0 million in 2010, then jumped by 74.29% to $24.4 million in 2011, then climbed by 6.97% to $26.1 million in 2012.
  • The last three Interest & Investment Income figures came in at $26.1 million (Q1 2012), $24.4 million (Q4 2011), and $22.2 million (Q3 2011), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 229.00 Mn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -645.00 Mn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2012 26.10 Mn
Dec 31, 2011 24.40 Mn
Sep 30, 2011 22.20 Mn
Jun 30, 2011 17.80 Mn
Mar 31, 2011 15.50 Mn
Dec 31, 2010 14.00 Mn
Sep 30, 2010 16.30 Mn
Jun 30, 2010 11.00 Mn
Mar 31, 2010 10.60 Mn
Sep 30, 2009 718.70 Mn
Jun 30, 2009 18.80 Mn